Due to an oversight, a part of the above article was omitted from the last issue of the journal. We are now rectifying this omission.
Levamisole
The relative efficacy of levamisole is not known. In the University Paediatric unit, at the Lady Ridgeway Hospital for Children, we have been using this drug since 1993. A 10 year review of 110 children with SSNS followed up by us showed that levamisole was able to induce remissions lasting 2 years or longer and there was no statistically significant difference in efficacy when compared with cyclophosphamide 14 .
However, it appears as though levamisole is more effective in the milder forms of the disease. We have not encountered any serious side effects with this drug to date 14 .
Cyclosporin A This drug is nephrotoxic and therefore can be used only if facilities are available to monitor drug levels very regularly. The Medical Research Institute has recently commenced assessing blood levels of cyclosporin, but this is done only on 2 specified days of the week. The very high cost of the drug and the problems of assessing blood levels regularly makes it difficult for us, in Sri Lanka, to use this drug at present. __________________________________________ 1 Senior Lecturer in Paediatrics, Faculty of Medicine, University of Colombo.
WHAT WE NOW KNOW
• Children with frequent relapses usually remain steroid responsive4.
• There are no randomized controlled trials comparing repeated courses of standard relapse therapy with long term low dose alternate day prednisolone therapy for frequent relapses.
• 8 week courses of cyclophosphamide or chlorambucil and prolonged courses of cyclosporin or levamisole substantially reduce the incidence of relapses 13 .
• Cyclosporin and levamisole effectively induce remission, but are unable to sustain this effect once treatment is withdrawn 13 .
• There is insufficient data at present to show that alkylating agents are more effective than cyclosporin or levamisole in reducing the incidence of relapses 13, 14 .
Treatment protocol for children with SSNS
This protocol is a modified version of the guidelines set out by the British Association for Paediatric Nephrology and Research Unit 15 . 
